The Saudi Food and Drug Authority (SFDA) has officially approved the registration of Foundayo, an oral medication designed to assist in weight management. This move is part of the Kingdom's broader Health Sector Transformation Programme, which aims to improve public health outcomes in line with Vision 2030. With recent data showing that over 20% of Saudi adults struggle with obesity, health officials believe this daily pill will serve as an effective tool for those who need support beyond traditional diet and exercise.

The medication functions by activating GLP-1 receptors in the body, which helps regulate blood sugar and curb appetite. While it offers a promising solution for patients struggling with weight-related health conditions, medical experts stress that it is not a "magic fix" and requires strict physician oversight. Before beginning treatment, patients must undergo thorough screenings, including blood tests and a review of their family medical history. Users should also be aware of potential side effects, such as nausea or abdominal discomfort, and those with a history of specific thyroid conditions are strictly advised against its use.